On CNBC's "Halftime Report Final Trades," Bryn Talkington, managing partner at Requisite Capital Management, named AbbVie ...

AbbVie Inc. (NYSE:ABBV) is one of the best cheap stocks to buy for beginners. AbbVie Inc. (NYSE:ABBV) announced on June 2 ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies ...

Ten years ago, AbbVie (NYSE:ABBV | ABBV Price Prediction) was a one-drug story. Humira, the world’s best-selling medicine, ...

AbbVie ABBV announced that the European Commission has approved Aquipta (atogepant) for the acute treatment of migraine in ...

However, AbbVie's financial results once again highlighted one of the company's strengths that investors should pay attention ...

AbbVie’s (ABBV) ovarian cancer therapy Elahere is OK'd for the U.K.'s National Health Service by the country's health ...

Abbvie announced an update on their ongoing clinical study. Claim 55% Off TipRanks. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and for ...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...

AbbVie Inc. (NYSE:ABBV) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. AbbVie Inc.

AbbVie's antibody-drug conjugate (ADC) Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, with hundreds of women every year expected to be eligible for ...